ABSTRACT PITTMAN, MARGARET (National Institutes of Health, Bethesda, Md.), AND CLAIRE B. Cox. Pertussis vaccine testing for freedom-from-toxicity. Appl. Microbiol. 13:447-456. 1965.-The results of 9.5 years of official testing of vaccines containing pertussis vaccine, plain or adsorbed with alum, AI(OH)3, or AlPO4, are reported. Toxicity was evaluated by weight changes in mice at 3 and 7 days after injection and intercurrent deaths. Toxicity was encountered during the early use of AlPO4 in pertussis vaccine products, with a special product and quadruple-antigen vaccines. Throughout the study Al(OH)3 products, few in number, were the least reactive of the adsorbed products. The slopes of regression lines of graded-dose responses reflected variations in reactivity of "nontoxic" vaccines. The U.S.-prescribed test is discussed relative to the (i) reactivity in children, (ii) causes of toxicity, (iii) other assays for pertussis vaccine toxicity, and (iv) the use of a reference vaccine in the toxicity test.
Bordetella pertussis is unique among infectious bacteria in its marked ability to modify biological responses. (See reviews, Pittman, 1957; Kind, 1958.) Hence, there has been special concern that pertussis vaccine be as free as possible from reactive factors and yet provide adequate protection against whooping cough. Among the known reactive substances are a heat-labile dermonecrotic toxin, an endotoxin which is common to all gram-negative bacteria and specific and nonspecific sensitizing factors, including the histamine-sensitizing factor (HSF). Although not proven, HSF has been suggested as being a contributor to the neurological symptoms sometimes observed in whooping cough and after vaccination. Fortunately, encephalopathy after vaccination is relatively rare.
At a Round Table Conference on Pertussis Immunization, Prague, Czechoslovakia, 1962, as well as at a Pertussis Vaccine Symposium, Bethesda, Md., 1963, emphasis was placed on untoward reactions that may be induced by pertussis vaccine in man, the lack of a clear definition of the nature of the cause of these reactions, and the need for laboratory tests that would be precisely correlated with the chemical and antigenic properties of the components of the vaccine and the correlation of these assays with untoward reactions in children.
The purpose of this report is to give the experience of the Division of Biologics Standards (DBS) in toxicity testing of products containing pertussis vaccine and to discuss the causes of toxicity, the relation of laboratory assays to untoward reactions in children, and proposed changes to provide better precision in the toxicity test.
Methods of assay for toxicity were studied during the development of U.S. requirements for pertussis vaccine more than 15 years ago. With use of experimental vaccines, it was found that loss of rabbit dermonecrotic toxicity of the vaccine was correlated with weight gain in mice (Pittman, 1952) . In general, when 1.0 opacity unit (OU) failed to induce dermonecrosis in rabbits, mice injected intraperitoneally with 10 OU weighed no less than initially at the end of 72 hr and more than initially at the end of 7 days, and without intercurrent deaths. ( The opacity of the U.S. Opacity Standard was adjusted to be equivalent to the opacity of aged pertussis vaccines containing 10,000 million bacteria per milliliter as determined by direct count. A freshly prepared suspension of bacteria of equivalent density contains about one-third fewer bacteria. The opacity of a vaccine is measured within 2 weeks after harvest of the bacteria and usually within 48 hr.) These and the plain vaccine up to 10 OU. (The bulk bacterial suspension was tested by the manufacturer at a dose of 10 OU.) The average weight change per mouse was calculated from the difference between group weights at the time of injection and at the observed period. Deaths were recorded at 7 days and also at 14 days in the first period analyzed.
A vaccine was accepted as free from toxicity if at the end of 72 hr the group weight of the mice was no less than initially, and at the end of 7 days, preceding the 1961 revision, the group weight was greater than initially and there were no vaccine-related deaths, and after the 1961 revision, the average mouse weight gain was no less than 3.0 g and mortality was no greater than 5%.
If a lot failed to pass on the first test, the test(s) was repeated. All results were used to determine acceptance or rejection of the lot. Repetitions are reflected in the results given below where the average number of mice per lot exceeded 10.
Graded dose response. Groups of mice were given graded doses of a vaccine and observed as for the single-dose test. Dose-regression curves were calculated for the 7-day weight gains by the formula y = a + bx with a log transformation of dose.
RESULTS
Saline control mice. (Medical Research Council 1956 , 1959 .
The combined results of the tests of the lots of plain vaccines of all manufacturers, with the two t Number of tests which differ from number observed at 7 days is enclosed in parentheses. products (Table 5 ). Toxicity was marked by slow weight gain after 3 days and late deaths. During the last 2-year period the weight gains were satisfactory. As a whole, the DTP-P lots were more toxic than those of the other products. Certain lots were unsatisfactory for release. Figure 1 gives an overall picture of the pertussis vaccine products, except DTP-P, for the four periods studied. It is of special interest to note that the average weight gains for all types of products (except for the AlPO4 products in the 1.5-year period and the special alum product) prior to the reduction in test dose in 1961 would have satisfied the 1961 specified weight gain of 3.0 g. Weight gains for the customary alum products have remained remarkably constant. In the last period, the AI(OH)3 and AlPO4 products have shown an increase in weight which, no doubt, was influenced by the decrease in test dose, 0.3 to 0.25 ml, and an increase in the growth rate of the mice as evidenced by weight gain of the control mice (Table 1) . Al(OH)3 products have been the least reactive.
Graded dose response. The sensitivity of mice to small changes in test doses of borderline toxic vaccines is illustrated by the regression dose curves in Fig. 2 , which were calculated from data given by Gerwe (1961) . The intersection of the weight line and 3.0 g is at 0.26 ml and the mortality is 4.3%. A vaccine of this reactivity would be acceptable. However, a vaccine so near the lower limit of acceptability would need to be tested with 50 or more mice in order to prevent rejection of a nontoxic vaccine or acceptance of a toxic vaccine. Fortunately, very few lots submitted for release are of borderline toxicity.
In 1962-63, graded dose responses of each manufacturer's product were determined. No fewer than three lots per product were tested, with use of three doses and 30 mice per dose per lot. The weight gains at 7 days for similar products were combined and plotted (Fig. 3) . The lines of the four types of products were parallel. The individual products, however, showed differences in reactivity (Fig. 4) Information on the relation of animal assays to reactions in children is inadequate. Cohen (1963) reported two instances in which the mouse test reflected a difference in the reactivity of vaccines for children. Toxic reactions occurred more frequently both with AlPO4-adsorbed DTP (16 OU/SHD) than with plain P (20 OU/SHD), and with plain vaccine prepared with bacteria grown in a fluid medium than with plain vaccine prepared with bacteria grown on solid medium.
Using two vaccines that passed the toxicity test, J. A. Bell and M. Pittman observed that the percentage of children with temperature equal to or greater than 101.6 F was slightly higher with a vaccine that showed in mice gradations in weight-gain response related to size of test dose than with another vaccine in which response was not graded (Reported by M. Pittman, Prague Conference, 1962) .
On the other hand, the Research Committee on Pertussis Vaccine, Japan, failed to show a correlation between results of several laboratory tests (but different from the U.S. test) and temperature rises in children measured 24 hr after injection (reported by J. Kaneko, Prague Conference, 1962).
Production of satisfactory pertussis vaccine is influenced by the interplay of many factors: bacterial strain(s), medium, method of detoxification, preservative, adjuvant, and inherent factors within a laboratory. A few selected but not inclusive references are cited. Bacterial strains vary in protective antigenicity (Kendrick, Updyke, and Eldering, 1949) . There is inadequate information on protective activity of strains that differ in toxicity and the influence of these strains on toxicity of final product. Cohen's observations on the greater toxicity of vaccines prepared from bacteria grown in a liquid medium versus bacteria grown on a solid medium were cited above. The former was also more potent.
Age of bacteria at time of harvest, no doubt, has an effect on the permeability of the cell wall, thereby influencing toxicity. Detoxification by heating for 30 to 60 min at 56 C is more effective than heating for several days at 37 C (Pittman, 1952; Cohen, 1963) . Besides effect on dermonecrotic toxin, the heating at 56 C may inhibit deleterious enzymatic activity. Vaccine heated at 35 C and preserved with Merthiolate retained potency better than did unpreserved vaccine (Gardner, 1964) .
Recent work has shown that pertussis vaccine in DTP-P preserved with benzethonium chloride is unstable in potency (Olson, Eldering, and Graham, 1964; Gardner, 1964) . This surfaceacting preservative, no doubt, contributed to the greater toxicity of DTP-P reported in this paper and by Pittman (1962) by favoring the leaching of the toxin from the bacterial cell. It is well known that alkalinity favors lysis and thereby promotes toxicity. Niwa, Yamadeya, and Kuwajima (1964) reported the influence of various substances on leakage and inhibition of leakage.
Merthiolate apparently acts as a stabilizer of potency (Gardner, 1964) . It is the most effective preservative known for pertussis vaccine. In its presence vaccines stored at 4 C gradually decrease in toxicity. This, however, may require several months (e.g., Pittman, 1952, and 
others).
Formalin is effective in detoxification, but it can have an adverse effect on potency (Pittman, 1952; Jo6, Pusztai, and JuhAsz, 1961; unpublished results) . However, with precaution, it can be used without apparent deleterious effect (PekArek and Moheska, 1961) .
Results in this report show that aluminum salt adjuvants differ in their effect on the mouse toxicity of pertussis vaccine. AlPO4 has caused the greatest difficulty. Differences within a manufacturer's product, but not necessarily between manufacturers' products, were related to the amount of adjuvant present. Cohen (1963) observed that AlPO4 vaccine, although low in reactivity in children, was more so than plain vaccine. Joo et al. (1961) showed that the strong alkalinity that arises when the AlPO4 gel is produced in statu nascendi, as contrasted with use of preformed AlPO4 gel, affects potency. The alkalinity, which may reach pH 14, would favor toxicity.
Differences in potency from lot to lot of a manufacturer's product (e.g., Cohen, 1963) (Katsampes, Brooks, and Bradford, 1942; Andersen, 1952) . In a comparison of the suckling mice test with the intraperitoneal injection of adult mice (U.S. test), Andersen (1958) found that the latter not only acted as a measure of the effect of the known toxin but also of less well defined toxic substances which cause a decrease in resistance of mice to histamine and a homologous sensitization.
In the early work of the National Institute of Public Health in the Netherlands, toxicity was measured by response of guinea pigs to intraperitoneal injection of vaccine; this was followed by a guinea pig subcutaneous test (Cohen, 1963) . Cohen reported, however, that the U.S. test was more sensitive in discovering traces of toxin.
Pek6rek and Reza6bek (1959) and J. Pekdrek et al. (Prague, 1962) determined toxicity by titration of vitamin C clearance from rat adrenals. Results correlated with rat foot edema. Maximal reactions of both tests were obtained at 4 hr. Results of these tests also correlated with LD50 of the vaccine, but not necessarily with rabbit skin reactivity. The supernatant liquid of a fluid culture which caused decrease in vitamin C had no effect on the rabbit skin, whereas the sedimented bacterial cells innocuous in the stress test caused rabbit skin necrosis. We consider that the latter difference was due, at least in part, to the availability of the toxin. The toxin in the bacteria would not be readily available for the stress measurement, whereas it would be liberated from the bacteria localized in the skin. Pyrogenicity testing has been used with experimental preparations (Billaudelle et al., 1960; Barta, 1963) . Correlation with human reactivity has not been reported.
The role of the HSF in reactivity of children remains an enigma. This factor is closely associated with the protective antigen. Munoz (1963) considered that the two form an antigen complex. However, in certain preparations the two factors appear in different proportions (Pittman, 1951, and Prague 1962; Cohen, 1963) . Dolby (1958) has claimed separation. All commercial vaccines, however, do have HSF, and the question arises, should there be a prescribed maximal level of acceptability? By the specification of an upper limit on the estimated potency of a vaccine, the amount of HSF in U.S. vaccines has, to some extent, been restricted.
In spite of limitations of an absolute test without a base line of reference, the lack of agreement between DBS and the manufacturers in the assessment of toxicity has been limited largely to individual products and then only with lots of borderline toxicity. As a whole, vaccines have been and are well above the lower limit of acceptability. However, with the 1961 revised requirements, the limitations of an absolute test have become more prominent.
Mice of different strains vary or change in response to the vaccine. With the same dose of a common vaccine, but with different strains of mice, seven manufacturers observed mortality ranging from 4 to 43% (H. D. Piersma, Prague, 1962) . With NIH-BS mice we obtained 2% mortality (unpublished data). Andersen (1952) , Kurokawa et al. (1962a) , and others reported variations in toxicity response of different strains of mice. Mice with a high degree of toxin susceptibility also respond poorly to immunization (Pittman, 1962) . That a strain of mouse may change in weight response was shown in this report by a significant increase in the rate of growth of the saline control mice. Such a change would tend to influence the acceptance of vaccines when a specified weight gain is required. Whether or not this change was due to improved air-conditioned quarters in 1960 or a change in diet is not known. Cohen (1963) Another deterring factor in the selection of a reference preparation has been the lack of information on the correlation of laboratory assay results with untoward reactions in children, and, also, what toxic component is responsible for human reactivity. Nevertheless, two vaccine preparations have been dried, and their toxic properties are being characterized by different assay procedures.
It is anticipated that a cooperative field study will be initiated after a base line of reference has been established. It is hoped that the clinical study will determine whether or not there is a correlation between the laboratory assay and untoward reactions in children.
